Late-breaking abstract: The prevail study: Primary and non-visceral / visceral disease subgroup results for enzalutamide-treated men with metastatic prostate cancer (MPC) that had progressed on adt

This article has no abstract
Epistemonikos ID: af72eabffcdefa1467e5fa005e599344b94f0e69
First added on: Feb 05, 2025